This win strengthens Devyser’s footprint in the Nordic region and supports the expansion of high-quality, fast, and reliable CFTR testing within established national newborn screening programs. Cystic fibrosis is one of the most common genetic disorders in Europe, with a prevalence of 1 in 2000–3000 newborns*, depending on the region. Early detection is essential, and genetic testing plays a central role in confirming CF diagnoses, identifying carriers, and enabling clinicians to understand the specific CFTR variants involved. 

“This tender win shows the trust placed by Oslo University Hospital in Devyser’s CFTR assay to support Norway’s commitment to aid early CF detection and improved pediatric care” said, Jan Wahlström, CEO, Devyser. 

“This year we have seen a lot of positive development in Norway with Q3 YTD revenues tripling compared to 2024. I’m pleased to see yet another incremental deal closed in a market poised for increased growth” said Theis Kipling, CCO Devyser.

About Devyser CFTR 
Devyser CFTR is an NGS test used in the confirmation of cystic fibrosis and screening of genetic variants in newborns and adults. Devyser CFTR NGS captures all clinically relevant cystic fibrosis gene mutations in a single assay that is purpose-designed for fast and efficient lab processing. 

^{* Santos V, Cardoso AV, Lopes C, Azevedo P, Gamboa F, Amorim A. Cystic fibrosis - Comparison between patients in paediatric and adult age. Rev Port Pneumol (2006). 2017 Jan-Feb;23(1):17-21. doi: 10.1016/j.rppnen.2016.07.002. Epub 2016 Oct 13. PMID: 27743767.}